Renaissance Technologies - CYTOMX THERAPEUTICS INC ownership

Quarter-by-quarter ownership
Renaissance Technologies ownership history of CYTOMX THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$1,200
-37.9%
930,100
-17.1%
0.00%
-33.3%
Q2 2023$1,931
+50.4%
1,122,400
+32.0%
0.00%
+50.0%
Q1 2023$1,284
-40.1%
850,300
-36.6%
0.00%
-33.3%
Q4 2022$2,145
-99.9%
1,340,774
-25.7%
0.00%
-25.0%
Q3 2022$2,618,000
-1.6%
1,805,600
+24.2%
0.00%
+33.3%
Q2 2022$2,661,000
+11.2%
1,454,261
+62.3%
0.00%0.0%
Q1 2022$2,392,000
+9.3%
895,900
+77.2%
0.00%0.0%
Q4 2021$2,189,000
-51.9%
505,500
-43.5%
0.00%
-50.0%
Q3 2021$4,554,000
-29.9%
894,600
-12.8%
0.01%
-25.0%
Q2 2021$6,496,000
-42.1%
1,026,200
-29.4%
0.01%
-42.9%
Q1 2021$11,228,000
-17.0%
1,452,568
-29.6%
0.01%
-6.7%
Q4 2020$13,522,000
-11.8%
2,064,500
-10.4%
0.02%0.0%
Q3 2020$15,326,000
-21.7%
2,304,600
-2.0%
0.02%
-11.8%
Q2 2020$19,581,000
+15.6%
2,350,671
+6.5%
0.02%
+6.2%
Q1 2020$16,935,000
-1.2%
2,208,000
+7.0%
0.02%
+23.1%
Q4 2019$17,146,000
+51.6%
2,063,271
+34.7%
0.01%
+30.0%
Q3 2019$11,308,000
-28.4%
1,532,300
+8.9%
0.01%
-28.6%
Q2 2019$15,787,000
+13.8%
1,407,000
+9.0%
0.01%
+7.7%
Q1 2019$13,874,000
-30.3%
1,290,600
-2.1%
0.01%
-40.9%
Q4 2018$19,899,000
-29.3%
1,317,800
-13.3%
0.02%
-24.1%
Q3 2018$28,129,000
-52.8%
1,520,500
-35.9%
0.03%
-12.1%
Q2 2018$59,613,000
+118.0%
2,372,700
+146.8%
0.03%
+10.0%
Q1 2018$27,346,000
+81.1%
961,200
+34.4%
0.03%
+76.5%
Q4 2017$15,096,000
+54.5%
715,100
+32.9%
0.02%
+41.7%
Q3 2017$9,774,000
+53.5%
537,900
+30.9%
0.01%
+50.0%
Q2 2017$6,369,000
+57.1%
410,900
+75.0%
0.01%
+33.3%
Q1 2017$4,055,000
+304.7%
234,800
+157.5%
0.01%
+200.0%
Q4 2016$1,002,00091,2000.00%
Other shareholders
CYTOMX THERAPEUTICS INC shareholders Q4 2023
NameSharesValueWeighting ↓
BVF INC/IL 5,803,700$25,130,0000.91%
Altium Capital Management LP 663,800$2,874,0000.79%
Rubric Capital Management LP 2,406,449$10,420,0000.49%
RTW INVESTMENTS, LP 6,029,700$26,109,0000.38%
Orbimed Advisors 3,214,509$13,919,0000.18%
TANG CAPITAL MANAGEMENT LLC 152,345$660,0000.13%
PLATINUM INVESTMENT MANAGEMENT LTD 980,085$4,244,0000.12%
Point72 Asset Management, L.P. 6,303,025$27,292,0000.11%
Sender Co & Partners, Inc. 40,720$176,0000.09%
Manteio Capital LLC 15,067$65,0000.08%
View complete list of CYTOMX THERAPEUTICS INC shareholders